Treating percutaneous coronary intervention-related myocardial injury with metformin.
作者信息
Calvert John W
机构信息
Division of Cardiothoracic Surgery, Department of Surgery, Carlyle Fraser Heart Center, Emory University School of Medicine, Atlanta, Ga., USA.
出版信息
Cardiology. 2014;127(2):130-2. doi: 10.1159/000356875. Epub 2013 Dec 5.
Abstract
摘要
相似文献
1
Treating percutaneous coronary intervention-related myocardial injury with metformin.
Cardiology. 2014;127(2):130-2. doi: 10.1159/000356875. Epub 2013 Dec 5.
2
The effect of metformin on cardiac fibrosis via differentiation of cardiac fibroblasts.
Cardiology. 2015;130(1):52-3. doi: 10.1159/000369127. Epub 2014 Dec 13.
3
Response to the paper by Ünlü et al. entitled 'The effect of metformin on cardiac fibrosis via differentiation of cardiac fibroblasts'.
Cardiology. 2015;130(1):54. doi: 10.1159/000369297. Epub 2014 Dec 13.
4
Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention.
Cardiology. 2014;127(2):133-9. doi: 10.1159/000355574. Epub 2013 Dec 5.
5
[The effect of metformin on myocardial tolerance to ischemia in rats with diabetes mellitus type 2].
Patol Fiziol Eksp Ter. 2013 Oct-Dec(4):32-4.
6
Metformin therapy in diabetes: the role of cardioprotection.
Curr Atheroscler Rep. 2013 Apr;15(4):314. doi: 10.1007/s11883-013-0314-z.
7
The cardioprotective effects of metformin.
Curr Opin Lipidol. 2011 Dec;22(6):445-53. doi: 10.1097/MOL.0b013e32834ae1a7.
8
Promising strategies to minimize reperfusion injury in STEMI.
Minerva Cardioangiol. 2016 Jun;64(3):284-94. Epub 2016 Feb 9.
9
Myocardial protection from ischemia-reperfusion injury post coronary revascularization.
Expert Rev Cardiovasc Ther. 2015;13(9):1045-57. doi: 10.1586/14779072.2015.1070669. Epub 2015 Jul 22.
10
Statin and myocardial ischemia-reperfusion injury.
Int J Cardiol. 2016 Nov 1;222:988. doi: 10.1016/j.ijcard.2016.08.143. Epub 2016 Aug 8.
本文引用的文献
1
Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention.
Cardiology. 2014;127(2):133-9. doi: 10.1159/000355574. Epub 2013 Dec 5.
2
AMP-activated protein kinase regulation and biological actions in the heart.
Circ Res. 2012 Aug 31;111(6):800-14. doi: 10.1161/CIRCRESAHA.111.255505.
3
Myocardial infarction due to percutaneous coronary intervention.
N Engl J Med. 2011 Feb 3;364(5):453-64. doi: 10.1056/NEJMra0912134.
4
Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented?
Heart. 2010 May;96(10):736-40. doi: 10.1136/hrt.2009.186189.
5
Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.
J Am Coll Cardiol. 2009 Dec 1;54(23):2157-63. doi: 10.1016/j.jacc.2009.07.005. Epub 2009 Aug 6.
6
Myocardial protection by nitrite.
Cardiovasc Res. 2009 Jul 15;83(2):195-203. doi: 10.1093/cvr/cvp079. Epub 2009 Feb 27.
7
Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure.
Circ Res. 2009 Feb 13;104(3):403-11. doi: 10.1161/CIRCRESAHA.108.190918. Epub 2008 Dec 18.
8
Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling.
Diabetes. 2008 Mar;57(3):696-705. doi: 10.2337/db07-1098. Epub 2007 Dec 14.
9
A study comparing the incidence and predictors of creatine kinase MB and troponin T release after coronary angioplasty. Does Clopidogrel preloading reduce myocardial necrosis following elective percutaneous coronary intervention?
Int J Cardiol. 2007 Mar 2;116(1):93-7. doi: 10.1016/j.ijcard.2006.05.001. Epub 2006 Jul 25.
10
Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy).
Am J Cardiol. 2006 Jun 1;97(11):1591-6. doi: 10.1016/j.amjcard.2005.12.050. Epub 2006 Apr 7.
Zotero 插件